Literature DB >> 225269

Cell-mediated immunity to varicella-zoster virus measured by virus inactivation: mechanism and blocking of the reaction by specific antibody.

A A Gershon, S P Steinberg.   

Abstract

The process whereby varicella-zoster (V-Z) virus is inactivated in vitro by immune human peripheral blood leukocytes stimulated with V-Z antigen was examined. It was found that stimulation of leukocytes by V-Z antigen, but not by other viral antigens, was required for inactivation of V-Z virus to occur. Viral inactivation could be blocked by addition of V-Z antiserum to either the stimulation phase of the reaction or the inactivation phase, further demonstrating the specificity of the reaction. In addition these blocking experiments suggested that modulation of V-Z membrane antigen by antiserum occurred with an accompanying loss of immunological recognition of virus-infected cells. Inactivation of V-Z virus in vitro in this study appeared not to be dependent upon the secretion of interferon or upon antibody-dependent cellular cytotoxicity. The specific cells required for V-Z inactivation were T lymphocytes and monocytes (macrophage precursors).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 225269      PMCID: PMC414433          DOI: 10.1128/iai.25.1.164-169.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  T-cell-mediated cytotoxicity against herpes simplex virus-infected target cells.

Authors:  K Pfizenmaier; A Starzinski-Powitz; M Röllinghoff; D Falks; H Wagner
Journal:  Nature       Date:  1977-02-17       Impact factor: 49.962

2.  Cellular immunity and herpesvirus infections in cardiac-transplant patients.

Authors:  K H Rand; L E Rasmussen; R B Pollard; A Arvin; T C Merigan
Journal:  N Engl J Med       Date:  1977-06-16       Impact factor: 91.245

3.  Interferon induction by vesicular stomatitis virus and its role in virus replication.

Authors:  J Vilcek; S Yamazaki; E A Havell
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

4.  Binding of sheep erythrocytes to human lymphocytes. A probable marker of T lymphocytes.

Authors:  S S Fröland
Journal:  Scand J Immunol       Date:  1972       Impact factor: 3.487

5.  Cutaneous interferon production in patients with Hodgkin's disease and other cancers infected with varicella or vaccinia.

Authors:  R W Armstrong; M J Gurwith; D Waddell; T C Merigan
Journal:  N Engl J Med       Date:  1970-11-26       Impact factor: 91.245

6.  Immunoglobulin and receptors for C3 on lymphocytes from patients with rheumatoid arthritis.

Authors:  O J Mellbye; R P Messner; J R DeBord; R C Williams
Journal:  Arthritis Rheum       Date:  1972 Jul-Aug

7.  Herpes zoster and impaired cell-associated immunity to the varicella-zoster virus in patients with Hodgkin's disease.

Authors:  J C Ruckdeschel; S C Schimpff; A C Smyth; M R Mardiney
Journal:  Am J Med       Date:  1977-01       Impact factor: 4.965

8.  Cell-mediated immunity to varicella-zoster virus demonstrated by viral inactivation with human leukocytes.

Authors:  A A Gershon; S Steinberg; M Smith
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

9.  The etiologic agents of varicella and herpes zoster; serologic studies with the viruses as propagated in vitro.

Authors:  T H WELLER; H M WITTON
Journal:  J Exp Med       Date:  1958-12-01       Impact factor: 14.307

10.  Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells.

Authors:  M Jondal; G Holm; H Wigzell
Journal:  J Exp Med       Date:  1972-08-01       Impact factor: 14.307

View more
  5 in total

1.  Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1979-07       Impact factor: 3.441

2.  Use of bone marrow fibroblasts to prepare targets for an HLA restricted-cytotoxicity assay system.

Authors:  R A Bowden; L McGavren; A R Hayward; M J Levin
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

3.  Inhibition of varicella-zoster virus in vitro by human peripheral blood mononuclear cells.

Authors:  G P Rabalais; F E Berkowitz; A R Hayward; M J Levin
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

4.  Inactivation of varicella zoster virus in vitro: effect of leukocytes and specific antibody.

Authors:  A A Gershon; S P Steinberg
Journal:  Infect Immun       Date:  1981-08       Impact factor: 3.441

5.  Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka.

Authors:  Gathsaurie Neelika Malavige; Louise Jones; S D Kamaladasa; A Wijewickrama; S L Seneviratne; Antony P Black; Graham S Ogg
Journal:  PLoS One       Date:  2008-11-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.